Assay News and Research

RSS

IgG antibodies reduce viral load of SARS-CoV-2

A study conducted by researchers at the University of Washington has highlighted the importance of serological testing for infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

26 May 2020

Heparin may stop SARS-CoV-2 infecting host cells

Researchers at the University of Sheffield have developed a new assay that can be used to assess the attachment of viruses to host cells and to test potential inhibitors of viral infection.

24 May 2020

Changes in antibodies and RNA shedding during early SARS-CoV-2 infection

As the COVID-19 pandemic and its far-reaching implications continue to unfold globally and disrupt our normal way of life, scientists and researchers are racing to find an appropriate vaccine or therapeutic drug. This process involves understanding how the virus interacts with the host cell, the dynamics of the host immune response, and the eventual outcome.

22 May 2020

Preparing to meet SARS-CoV-2 head-on with a panel of neutralizing antibodies

A new study published on the preprint server bioRxiv in May 2020 describes a panel of neutralizing antibodies that bind to multiple attachment sites on the spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the current COVID-19 disease pandemic.

22 May 2020

Prediction of incubation period for COVID-19 and other viruses

A new study published on the preprint server bioRxiv* in May 2020 provides a method to estimate the incubation period for any new pathogen, which could help to define the optimal quarantine period necessary to keep the spread of the causative agent in check.

22 May 2020

ELISA and CLIA antibody tests for SARS-CoV-2 perform best in terms of sensitivity

Testing for those who have developed antibodies against the coronavirus can help tackle the ongoing COVID-19 pandemic. Now, a new study has identified all the antibody tests available for the coronavirus disease (COVID-19) to determine which performs better and is more accurate.

21 May 2020

Study shows selenium-containing compounds inhibit SARS-CoV-2 replication and assembly

A recent paper by researchers from the Netherlands and Poland provides evidence that modified ebselen derivatives may serve as highly promising prospective drugs against coronavirus disease 2019 (COVID-19). The manuscript is freely available on the bioRxiv* preprint server.

21 May 2020

Producing virus-specific antibodies after COVID-19

In order to design effective vaccines for COVID-19, we need to understand our immune responses. News-Medical speaks to Professor Chen Dong to find out more.

21 May 2020

Bio-Techne and Kantaro Biosciences announce partnership to develop and scale production of COVID-19 serology test

Bio-Techne Corporation and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced a partnership to initiate scaled manufacturing and distribution of testing kits based on the Mount Sinai-developed COVID-19 serology test.

From Bio-Techne 21 May 2020

Saliva testing allows quick, accurate and non-invasive SARS-CoV-2 detection

Saliva is one of the ways people can transmit the novel coronavirus to others, but it may also help combat coronavirus disease (COVID-19). Scientists are now looking into using saliva to test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent for COVID-19 disease.

20 May 2020

ChIP kits for high throughput antibody validation

Porvair Sciences report how its Chromatrap® ChIP kits provide an outstanding solution for antibodies suppliers looking to validate the performance of the antibodies they produce for chromatin immunoprecipitation (ChIP) assay kits.

From Porvair Sciences Limited 20 May 2020

Mount Sinai venture to develop and scale distribution of COVID antibody test kits

Mount Sinai Health System ("Mount Sinai") and Renalytix AI today announced the formation of Kantaro Biosciences, LLC ("Kantaro"), a Mount Sinai venture, to develop and scale production and distribution of a test kit based on the Mount Sinai-developed high-performance serologic assay for SARS-CoV-2 antibodies.

20 May 2020

SMART researchers awarded NMRC funding to develop rapid paper-based COVID-19 tests

Singapore-MIT Alliance for Research and Technology, MIT's research enterprise in Singapore, has received a grant from the National Medical Research Council COVID-19 Research fund for the acceleration of research and development of rapid paper-based serological and diagnostic tests for COVID-19.

18 May 2020

Novel insights on SARS-CoV-2 cell entry may inform further vaccine and treatment development

A research group from Harvard Medical School reported two cryo-electron microscopy structures derived from a single preparation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein in their paper available on the preprint server bioRxiv. Understanding the nuances of prefusion and postfusion conformations shed light on viral cell entry and may, in turn, guide the development of vaccines and drugs.

18 May 2020

Study shows human monoclonal antibodies can effectively neutralize SARS-CoV-2

US researchers have published a proof of concept on the efficacy of human monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in laboratory conditions, as well as their pioneering use in a mouse model. The study is available on the preprint server bioRxiv*.

17 May 2020

COVID-19 patients at high risk for developing complications associated with blood clots

When researchers from the University of Colorado Anschutz Medical Campus, Aurora, used a combination of two specific blood-clotting tests, they found critically ill patients infected with Coronavirus Disease 2019 (COVID-19) who were at high risk for developing renal failure, venous blood clots, and other complications associated with blood clots, such as stroke.

15 May 2020

Developing a COVID-19 antigen test

News-Medical speaks to Alastair Smith, the CEO of Avacta, about the process behind their newly developed antigen test for COVID-19.

From Avacta Life Sciences Ltd. 15 May 2020

ChIP kits for high throughput antibody validation

From Porvair Sciences Limited 15 May 2020

Using supercomputers to screen drugs for deadly heart arrhythmias

Death from sudden cardiac arrest makes headlines when it strikes athletes. But it also causes the most deaths by natural causes in the U.S. estimated at 325,000 per year.

14 May 2020

Researchers identify CoV Mac1 proteins as a potential SARS-CoV-2 drug target

A recent study by researchers at the University of Kansas and published on the preprint server bioRxiv* reveals that Mac1 protein implicated in the infection process of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a strikingly similar structure and activity in all coronaviruses – suggesting that possible future treatments targeting this protein may exert broad antiviral activity.

13 May 2020

Assay News and Research

IgG antibodies reduce viral load of SARS-CoV-2

Heparin may stop SARS-CoV-2 infecting host cells

Changes in antibodies and RNA shedding during early SARS-CoV-2 infection

Preparing to meet SARS-CoV-2 head-on with a panel of neutralizing antibodies

Prediction of incubation period for COVID-19 and other viruses

ELISA and CLIA antibody tests for SARS-CoV-2 perform best in terms of sensitivity

Study shows selenium-containing compounds inhibit SARS-CoV-2 replication and assembly

Producing virus-specific antibodies after COVID-19

Bio-Techne and Kantaro Biosciences announce partnership to develop and scale production of COVID-19 serology test

Saliva testing allows quick, accurate and non-invasive SARS-CoV-2 detection

ChIP kits for high throughput antibody validation

Mount Sinai venture to develop and scale distribution of COVID antibody test kits

SMART researchers awarded NMRC funding to develop rapid paper-based COVID-19 tests

Novel insights on SARS-CoV-2 cell entry may inform further vaccine and treatment development

Study shows human monoclonal antibodies can effectively neutralize SARS-CoV-2

COVID-19 patients at high risk for developing complications associated with blood clots

Developing a COVID-19 antigen test

ChIP kits for high throughput antibody validation

Using supercomputers to screen drugs for deadly heart arrhythmias

Researchers identify CoV Mac1 proteins as a potential SARS-CoV-2 drug target

eBook: Using iPSCs models for human disease research and drug discovery eBook

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News